Tvardi Therapeutics is trading at $0.98, up 14.05%, amid biotech-sector strength; available evidence points to sector and market sentiment, not a clear company-specific catalyst. - No company-specific announcement explaining the move was identified; the latest listed company release predates November 6. - The supplied sector update reports XBI gained 2.01%, alongside Moderna’s earnings beat and raised 2026 outlook. - The broader market was also positive, with the Nasdaq up 1.42%.